<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: -We considered the role of programmed ventricular stimulation (PVS) in primary prevention of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> (SCD) in an idiopathic <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:e sem="disease" ids="C0264793" disease_type="Disease or Syndrome" abbrv="IDC">IDCM</z:e>) population </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: -158 IDCM patients underwent PVS </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0004756'>Ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) was triggered in 44 patients (group I, 27.8%) versus 114 patients (group II) where VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> was not induced </plain></SENT>
<SENT sid="3" pm="."><plain>Sixty-nine <z:e sem="disease" ids="C0264793" disease_type="Disease or Syndrome" abbrv="IDC">IDCM</z:e> patients underwent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation: 41/44 in Group I and 28/114 in Group II </plain></SENT>
<SENT sid="4" pm="."><plain>The major end-points of the study were overall mortality and appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> activation </plain></SENT>
<SENT sid="5" pm="."><plain>Overall mortality during the 46.9 months of mean follow-up was not significantly different between the two groups </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with left ventriculat ejection fraction (LVEF) â‰¤35% (n=119) demonstrated a higher overall mortality rate compared to the patients with LVEF&gt;35% (n=39) (16.8% vs. 10.3%, log rank p=0.025) </plain></SENT>
<SENT sid="7" pm="."><plain>Advanced NYHA class (III-IV vs I-II) was the single independent and strongest prognostic factor of overall mortality (HR 11.909, p&lt;0.001, CI: 3.106-45.65), as well as of cardiac mortality (HR 14.787, p=0.001, CI: 2.958-73.922) </plain></SENT>
<SENT sid="8" pm="."><plain>Among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> recipients, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> activation rate was significantly higher in group I compared to group II (30/41 patients-73.2% vs. 5/28 patients-17.9%, log-rank p=0.001), either in the form of antitachycardia pacing (68.3% vs. 17.9%, log-rank p=0.001) or in the shock delivery form (51.2% vs. 17.9%, log-rank p=0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Induction of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> during PVS in contrast to LVEF was the single independent prognostic factor for future <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> activation (HR 4.195, p=0.007, CI: 1.467-11.994) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: -Inducibility of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> was associated with an increased likelihood of subsequent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> activation and SCD surrogate </plain></SENT>
</text></document>